


Dexamethasone

Chemical Properties

CAS No. :	50-02-2
Formula:	C ₂₂ H ₂₉ FO ₅
Molecular Weight:	392.46
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Dexamethasone is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory, immunosuppressive, and apoptosis-inducing activities. It inhibits the production of inflammatory miRNA-155 exosomes in macrophages, significantly reduces inflammatory cytokine expression in neutrophils and monocytes, suppresses LPS-induced macrophage inflammation, and induces autophagy. It is commonly used to induce animal models of depression, muscle atrophy, and hypertension, and holds potential in COVID-19 research.
Targets(IC50)	Glucocorticoid Receptor, Mitophagy, Antibacterial, Antibiotic, Autophagy, ADC Cytotoxin, Complement System, IL Receptor, SARS-CoV
In vitro	<p>METHODS: Human colorectal cancer cells LoVo and HCT116 were treated with Dexamethasone (10-300 μM) for 72 h. Cell growth inhibition was detected by MTT.</p> <p>RESULTS: Dexamethasone dose-dependently inhibited the growth of LoVo and HCT116 cells, and the inhibition rates of 300 μM Dexamethasone were 52.6% and 58.8%, respectively. [1]</p> <p>METHODS: Acute lymphoblastic leukemia cells RS4;11 were treated with Dexamethasone (100 nM) for 24-36 h. Cell morphology was examined using electron microscopy.</p> <p>RESULTS: In cells treated with Dexamethasone for 24 h, vesicles were surrounded by double membranes, which are characteristic of autophagosomes, and contained membrane structures and/or part of the endoplasmic reticulum or a large amount of cytoplasm. In addition to the appearance of autophagosomes, the nucleus and cell morphology were initially intact, suggesting that autophagosome formation preceded cell death. Dexamethasone induces autophagy. [2]</p> <p>METHODS: Activated mouse and human T cells were treated with Dexamethasone (0.001-10 μM) for 48 h, and PD-1 expression was detected by Flow Cytometry.</p> <p>RESULTS: Dexamethasone enhanced the expression of PD-1 in mouse and human activated T cells. [3]</p>
In vivo	<p>METHODS: To investigate the anti-inflammatory effects, Dexamethasone (1-10 mg/kg) was administered as a single intraperitoneal injection to LPS-induced inflammation in C57BL/6J Bom mice.</p> <p>RESULTS: 10 mg/kg Dexamethasone significantly reduced neutrophils in bronchoalveolar lavage fluid. Dexamethasone treatment significantly down-regulated the levels of TNF-α, IL-1α, IL-1β, IL-6, IL-12p40 and MIP-1α mRNA. Dexamethasone</p>

In vivo	exerts anti-inflammatory and antioxidant functions in acute airway inflammation. [4] METHODS: To detect anti-tumor activity in vivo, Dexamethasone (1 mg/kg) was intraperitoneally injected into SCID mice harboring the human myeloma tumor OPM2 five days per week for three weeks. RESULTS: Dexamethasone treatment significantly inhibited the growth of OPM2 tumors, indicating antitumor activity in vivo. [5]
Animal Research	NAC was administered at three different doses (10, 100 and 500 mg/kg body weight). At the highest concentration, the acidic pH of the NAC solution was adjusted by adding NaOH. Dexamethasone was administered as a single injection of 1 or 10 mg/kg. Both drugs were dissolved in saline and 400 µl were injected intraperitoneally, either 1 h before or 1 h after LPS exposure. In one experiment, NAC (100 and 500 mg/kg) was injected successively every 4·5 h, starting 1 h before challenge (five injections in total). A control group of LPS-exposed animals were injected intraperitoneally with solvent alone (saline). Intratracheal administration was performed by instillation of 100 µl NAC (50, 100 or 500 mg/kg) or dexamethasone (10 mg/kg) into the lungs of mice anaesthetized with 15 mg/kg Rapinovel (i.v.) [4].

Solubility Information

Solubility	H2O: insoluble Ethanol: 6 mg/mL (15.29 mM),Sonication is recommended. DMSO: 250 mg/mL (637.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.3 mg/mL (18.6 mM),Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.548 mL	12.7402 mL	25.4803 mL
5 mM	0.5096 mL	2.548 mL	5.0961 mL
10 mM	0.2548 mL	1.274 mL	2.548 mL
50 mM	0.051 mL	0.2548 mL	0.5096 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- He J, et al. Dexamethasone affects cell growth/apoptosis/chemosensitivity of colon cancer via glucocorticoid receptor α /NF- κ B. *Oncotarget*. 2017 Jun 28;8(40):67670-67683.
- Liu Z, Tan S, Zhou L, et al. SCGN deficiency is a risk factor for autism spectrum disorder. *Signal Transduction and Targeted Therapy*. 2023, 8(1): 1-15.
- Tian S, Wang R, Chen S, et al. Structural Basis for PPARs Activation by the Dual PPAR α / γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition. *Molecules*. 2021, 26(19): 6012.
- Sun C, Li X, Guo E, et al. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. *Oncogene*. 2019: 1-15.
- Li B, Zhou Q, Wan Q, et al. EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma. *Clinical Epigenetics*. 2023, 15(1): 187.
- Hou Z, Ren Y, Zhang X, et al. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia. *Cell Communication and Signaling*. 2024, 22(1): 211.
- Wu Y, He S, Zhang Y, et al. Sophoricoside ameliorates methicillin-resistant *Staphylococcus aureus*-induced acute lung injury by inhibiting Bach1/Akt pathway. *Phytomedicine*. 2024: 155846.
- Li P, Hu X, Fan Z, et al. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation. *Journal of Hematology & Oncology*. 2024, 17(1): 77.
- Chen S, Zhou X, Li W, et al. Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression. *Biochemical Pharmacology*. 2023: 115800.
- Laane E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. *Cell Death Differ*. 2009 Jul;16(7):1018-29.
- Xiong W, Jia L, Liang J, et al. Investigation into the anti-airway inflammatory role of the PI3K γ inhibitor JN-PK1: An in vitro and in vivo study. *International Immunopharmacology*. 2022, 111: 109102.
- Xing K, et al. Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. *BMC Immunol*. 2015 Jun 26;16:39.
- Wang C, Chen R, Zhu X, et al. METTL14 alleviates the development of osteoporosis in ovariectomized mice by upregulating m6A level of SIRT1 mRNA. *Bone*. 2022: 116652.
- Rocksén D, et al. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. *Clin Exp Immunol*. 2000 Nov;122(2):249-56.
- Kervoëlen C, et al. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. *Oncotarget*. 2015 Sep 29;6(29):26922-34.
- Huang L, Li Q. Notoginsenoside R1 promotes differentiation of human alveolar osteoblasts in inflammatory microenvironment through inhibiting NF- κ B pathway and activating Wnt/ β -catenin pathway. *Molecular Medicine Reports*. 2020, 22(6): 4754-4762
- Huang L, Li Q. Notoginsenoside R1 promotes differentiation of human alveolar osteoblasts in inflammatory microenvironment through inhibiting NF- κ B pathway and activating Wnt/ β -catenin pathway[J]. *Molecular Medicine Reports*. 2020, 22(6): 4754-4762.
- Li M, Yu H. Identification of WP1066, an inhibitor of JAK2 and STAT3, as a Kv1.3 potassium channel blocker. *British Journal of Pharmacology*. 2021 Jul;178(13):2617-2631. doi: 10.1111/bph.15441. Epub 2021 May 20.
- Zhang, Depeng, et al. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination[J]. *Biochemical pharmacology*. 2018 Aug;154:183-192.
- Zhang D, Li X, Hu Y, et al. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination. *Biochemical Pharmacology*. 2018, 154: 183-192
- Ding C, Fu S, Chen X, et al. Epigallocatechin gallate affects the proliferation of human alveolar osteoblasts and periodontal ligament cells, as well as promoting cell differentiation by regulating PI3K/Akt signaling pathway. *Odontology*. 2021 Jul;109(3):729-740. doi: 10.1007/s10266-021-00597-1. Epub 2021 Mar 6.
- Sun C, Li X, Guo E, et al. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis[J]. *Oncogene*. 2019: 1-15.
- Li M, Yu H. Identification of WP1066, an inhibitor of JAK2 and STAT3, as a Kv1.3 potassium channel blocker[J]. *British Journal of Pharmacology*. 2021
- Chen Q Z, Li Y, Shao Y, et al. TGF- β 1/PTEN/PI3K signaling plays a critical role in the anti-proliferation effect of tetrandrine in human colon cancer cells. *International Journal of Oncology*. 2017, 50(3): 1011-1021

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481